Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts

Abstract Background In the Phase III KRONOS study, triple therapy with budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) was shown to reduce exacerbations and improve lung function versus glycopyrronium/formoterol fumarate dihydrate (GFF) MDI in patients with moderate-to-v...

Full description

Bibliographic Details
Main Authors: Shigeo Muro, Hisatoshi Sugiura, Patrick Darken, Paul Dorinsky
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Respiratory Research
Subjects:
COPD
Asthma-like features
Triple therapy
Budesonide
Glycopyrrolate
Formoterol fumarate
Online Access:https://doi.org/10.1186/s12931-021-01773-1

Internet

https://doi.org/10.1186/s12931-021-01773-1

Similar Items